Figure 5From: Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell lineProliferation assay. TPC-1 cells were treated with RPI-1, dasatinib, or both for 24, 48, and 72 hours. After 72 hours, RPI-1 reduced TPC-1 cell proliferation by 70%, while dasatinib treatment resulted in a 60% reduction. The combination of the two drugs reduced the proliferation by 83%. The interaction was significant (p < 0.001).Back to article page